{{Rsnum
|rsid=6017787
|Chromosome=20
|position=46346057
|Orientation=plus
|GMAF=0.3875
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 5.3 | 48.7 | 46.0
| HCB | 10.3 | 50.0 | 39.7
| JPT | 13.3 | 46.0 | 40.7
| YRI | 39.2 | 50.3 | 10.5
| ASW | 38.6 | 54.4 | 7.0
| CHB | 10.3 | 50.0 | 39.7
| CHD | 12.8 | 39.4 | 47.7
| GIH | 13.9 | 44.6 | 41.6
| LWK | 52.7 | 34.5 | 12.7
| MEX | 6.9 | 51.7 | 41.4
| MKK | 48.7 | 38.5 | 12.8
| TSI | 10.8 | 38.2 | 51.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs6017787
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 176. Study population/ethnicity: 87 European descent Caucasians and 89 Yorubans. Significance metric(s): p = 0.00007. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109511
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs6017787
|overall_frequency_n=30
|overall_frequency_d=72
|overall_frequency=0.416667
|n_genomes=17
|n_genomes_annotated=0
|n_haplomes=23
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | Illumina Human 1M}}
{{on chip | NatGeo2}}